Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BOLT NASDAQ:FNCH NASDAQ:ITOS NASDAQ:PHAR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBOLTBolt Biotherapeutics$5.34+3.8%$5.52$4.59▼$14.36$10.24M0.914,890 shs4,883 shsFNCHFinch Therapeutics Group$12.40$12.57$10.15▼$15.85$19.91M1.22,172 shs5 shsITOSiTeos Therapeutics$10.15$10.16$4.80▼$17.63$448.73M1.311.51 million shsN/APHARPharming Group$14.43+3.8%$12.23$7.31▼$17.08$988.60M0.056,881 shs9,984 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBOLTBolt Biotherapeutics-2.65%+2.19%-0.19%-9.19%-60.12%FNCHFinch Therapeutics Group0.00%-2.13%-2.36%-7.68%+7.83%ITOSiTeos Therapeutics0.00%0.00%+0.40%+1.50%-16.12%PHARPharming Group+1.35%-6.52%+19.31%+24.22%+78.21%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBOLTBolt Biotherapeutics$5.34+3.8%$5.52$4.59▼$14.36$10.24M0.914,890 shs4,883 shsFNCHFinch Therapeutics Group$12.40$12.57$10.15▼$15.85$19.91M1.22,172 shs5 shsITOSiTeos Therapeutics$10.15$10.16$4.80▼$17.63$448.73M1.311.51 million shsN/APHARPharming Group$14.43+3.8%$12.23$7.31▼$17.08$988.60M0.056,881 shs9,984 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBOLTBolt Biotherapeutics-2.65%+2.19%-0.19%-9.19%-60.12%FNCHFinch Therapeutics Group0.00%-2.13%-2.36%-7.68%+7.83%ITOSiTeos Therapeutics0.00%0.00%+0.40%+1.50%-16.12%PHARPharming Group+1.35%-6.52%+19.31%+24.22%+78.21%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBOLTBolt Biotherapeutics 2.33Hold$47.50790.35% UpsideFNCHFinch Therapeutics Group 0.00N/AN/AN/AITOSiTeos Therapeutics 2.14Hold$15.5052.71% UpsidePHARPharming Group 3.00Buy$30.00107.90% UpsideCurrent Analyst Ratings BreakdownLatest BOLT, FNCH, OXB, PHAR, and ITOS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/15/2025BOLTBolt BiotherapeuticsLake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$75.008/7/2025ITOSiTeos TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$12.00 ➝ $11.007/21/2025ITOSiTeos TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/21/2025ITOSiTeos TherapeuticsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$12.00 ➝ $10.50(Data available from 9/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBOLTBolt Biotherapeutics$7.69M1.33N/AN/A$29.89 per share0.18FNCHFinch Therapeutics GroupN/AN/AN/AN/A$14.25 per shareN/AITOSiTeos Therapeutics$35M12.82N/AN/A$11.17 per share0.91PHARPharming Group$297.20M3.33$0.08 per share187.38$3.25 per share4.44Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBOLTBolt Biotherapeutics-$63.12M-$26.66N/AN/AN/AN/A-91.67%-53.19%11/11/2025 (Estimated)FNCHFinch Therapeutics Group-$74.75M-$8.82N/A∞N/AN/A-69.14%-26.92%N/AITOSiTeos Therapeutics-$134.41M-$4.67N/AN/AN/AN/A-33.26%-28.16%11/11/2025 (Estimated)PHARPharming Group-$11.84M-$0.13N/A481.00N/A-2.19%-3.31%-1.78%10/23/2025 (Estimated)Latest BOLT, FNCH, OXB, PHAR, and ITOS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025BOLTBolt Biotherapeutics-$6.40-$4.46+$1.94-$4.46$0.82 million$1.80 million8/6/2025Q2 2025ITOSiTeos Therapeutics-$1.12-$1.51-$0.39-$1.81N/AN/A7/31/2025Q2 2025PHARPharming Group-$0.10$0.06+$0.16$0.06$70.36 million$93.20 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBOLTBolt BiotherapeuticsN/AN/AN/AN/AN/AFNCHFinch Therapeutics GroupN/AN/AN/AN/AN/AITOSiTeos TherapeuticsN/AN/AN/AN/AN/APHARPharming GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBOLTBolt Biotherapeutics0.563.113.11FNCHFinch Therapeutics GroupN/A3.873.87ITOSiTeos TherapeuticsN/A7.537.53PHARPharming Group0.382.792.07Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBOLTBolt Biotherapeutics86.70%FNCHFinch Therapeutics Group21.77%ITOSiTeos Therapeutics97.16%PHARPharming Group0.03%Insider OwnershipCompanyInsider OwnershipBOLTBolt Biotherapeutics30.90%FNCHFinch Therapeutics Group44.90%ITOSiTeos Therapeutics14.20%PHARPharming Group2.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBOLTBolt Biotherapeutics901.92 million1.33 millionNot OptionableFNCHFinch Therapeutics Group1901.61 million885,000No DataITOSiTeos Therapeutics9044.21 million37.93 millionOptionablePHARPharming Group28068.51 million67.10 millionNot OptionableBOLT, FNCH, OXB, PHAR, and ITOS HeadlinesRecent News About These CompaniesPharming Group (NASDAQ:PHAR) Sees Unusually-High Trading Volume - Here's What Happened3 hours ago | marketbeat.comPharming Group (NASDAQ:PHAR) Stock Price Down 4.4% - Here's WhySeptember 16 at 7:32 PM | marketbeat.comHead to Head Survey: Pharming Group (NASDAQ:PHAR) versus Mersana Therapeutics (NASDAQ:MRSN)September 15 at 4:05 AM | americanbankingnews.comPharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Sees Significant Increase in Short InterestSeptember 14 at 7:59 AM | marketbeat.comPharming Group (NASDAQ:PHAR) Shares Gap Up - Still a Buy?September 13, 2025 | marketbeat.comPharming Group N.V.: Pharming Group promoted to the Euronext AMX indexSeptember 10, 2025 | finanznachrichten.dePharming Group promoted to the Euronext AMX® indexSeptember 10, 2025 | markets.businessinsider.comPharming Group N.V. (PHAR) Presents at H.C. Wainwright 27th Annual Global Investment Conference - SlideshowSeptember 8, 2025 | seekingalpha.comPharming Group (NASDAQ:PHAR) Shares Up 5% - Should You Buy?September 5, 2025 | marketbeat.comPharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Short Interest Down 73.1% in AugustSeptember 5, 2025 | marketbeat.comPharming Group (NASDAQ:PHAR) Shares Gap Down - Here's What HappenedSeptember 4, 2025 | marketbeat.comPharming Group to present at the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 3, 2025 | finance.yahoo.comPharming Group names new finance headSeptember 2, 2025 | msn.comPharming Group appoints Kenneth Lynard as Chief Financial OfficerSeptember 2, 2025 | markets.businessinsider.comWall Street Analysts See a 142.26% Upside in Pharming Group (PHAR): Can the Stock Really Move This High?August 22, 2025 | zacks.comPharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Sees Significant Growth in Short InterestAugust 17, 2025 | marketbeat.comPharming Group NV (PHARMA.XD) - Yahoo FinanceAugust 10, 2025 | finance.yahoo.comWall Street Analysts Think Pharming Group (PHAR) Could Surge 145.75%: Read This Before Placing a BetAugust 6, 2025 | zacks.comPharming Group N.V. Reports Strong Q2 EarningsAugust 4, 2025 | theglobeandmail.comPharming Group to participate in August investor conferenceAugust 4, 2025 | uk.finance.yahoo.comPharming Group Second Quarter 2025 Earnings: EPS: US$0.007 (vs US$0.002 loss in 2Q 2024)August 2, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 20253 Biotech Catalysts Present Major OpportunityBy Nathan Reiff | August 25, 2025JNJ Stock Surge Signals Confidence in New Growth PathBy Jeffrey Neal Johnson | August 25, 20253 Under-the-Radar Biotechs Under $5 That Could Soar 200%By Chris Markoch | September 9, 2025CoreWeave and Madrigal's Insider Trades Flash Bullish SignalsBy Leo Miller | September 10, 2025BOLT, FNCH, OXB, PHAR, and ITOS Company DescriptionsBolt Biotherapeutics NASDAQ:BOLT$5.34 +0.20 (+3.79%) Closing price 03:58 PM EasternExtended Trading$5.39 +0.05 (+1.03%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.Finch Therapeutics Group NASDAQ:FNCH$12.40 0.00 (0.00%) As of 09/16/2025Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.iTeos Therapeutics NASDAQ:ITOS$10.15 0.00 (0.00%) As of 08/29/2025iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.Pharming Group NASDAQ:PHAR$14.43 +0.53 (+3.81%) Closing price 03:57 PM EasternExtended Trading$14.43 0.00 (0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Hits Record High After CEO Hock Tan AI Pay Package CrowdStrike Stock Set for Breakout as Agentic AI Demand Surges Why CoreWeave's NVIDIA Deal Creates a Deep Moat for AI Investors Resideo Technologies: Institutional Activity Signals 30% Upside This Stock Quietly Benefits From Oracle and NVIDIA’s AI Surge Rezolute Stock: FDA Fast Track Fuels 2025 Breakout Lululemon’s Sell-Off Looks Overdone: A Contrarian Case This Defense Stock Is Up 113% This Year—Is It Still a Buy? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
